Opko Health News and Activities
Presence
Opko Health develops and sells pharmaceutical and diagnostic products. Its main offerings include specialty medicines, laboratory testing, and medical testing services for healthcare providers, patients, and research partners.
Opko Health products and services overview:
- Specialty medicines
- Diagnostic tests
- Laboratory services
- Biopharmaceutical products
- Medical devices
Revenue: ~$700 million
Employees: 3,500
Headquarters: Miami, United States (USA)
Opko Health is one of the...
Opko Health is a company listed under the stock ticker OPK (US).
Opko Health has a direct presence in 2 countries.Opko Health has 4 subsidiaries including Bio-Reference Laboratories, Eirgen Pharma and ModeX Therapeutics.
They are in:
- Pharmaceuticals40%
- Healthcare40%
- Other20%
Executives
View the org chart displaying its 50 main executives
Most searched biographies at Opko Health
- Phillip Frost, Chairman of the Board & Chief Executive Officer
- Prem Lachman, Director
- John Paganelli, Director
Create your alert
to follow the executive moves at Opko Health.
Pharmaceuticals
Opko Health has 1,912 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Opko Health
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
- OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
- OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
- Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
- OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
- Press Releases
- OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
- OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
- OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
- View more press releases Close
Social media about Opko Health
- Opko Health on Wikipedia, Google News & Yahoo Finance
- Opko Health on LinkedIn, X (Twitter) & YouTube
